References:
1. Flanigan KM. Duchenne and Becker muscular dystrophies. Neurologic clinics. 2014;32(3):671-88, viii.
2. Aartsma-Rus A, Van Deutekom JC, Fokkema IF, Van Ommen GJ, Den Dunnen JT. Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle & nerve. 2006;34(2):135-44.
3. Takeshima Y, Yagi M, Okizuka Y, Awano H, Zhang Z, Yamauchi Y, et al. Mutation spectrum of the dystrophin gene in 442 Duchenne/Becker muscular dystrophy cases from one Japanese referral center. Journal of human genetics. 2010;55(6):379-88.
4. Hoogerwaard EM, de Voogt WG, Wilde AA, van der Wouw PA, Bakker E, van Ommen GJ, et al. Evolution of cardiac abnormalities in Becker muscular dystrophy over a 13-year period. Journal of neurology. 1997;244(10):657-63.
5. de Souza F, Bittar Braune C, Dos Santos Nucera APC. Duchenne muscular dystrophy: an overview to the cardiologist. Expert review of cardiovascular therapy. 2020;18(12):867-72.
6. Escolar DM, Hache LP, Clemens PR, Cnaan A, McDonald CM, Viswanathan V, et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology. 2011;77(5):444-52.
7. Chamberlain JS. ACE inhibitor bulks up muscle. Nature medicine. 2007;13(2):125-6.
8. Hayes EA, Nandi D. Is there a future for the use of left ventricular assist devices in Duchenne muscular dystrophy? Pediatric pulmonology. 2021;56(4):753-9.